regulation

NHTSA proposed dropping the federal manual brake pedal mandate for purpose-built autonomous vehicles like Tesla's Cybercab, opening a public comment period through July 27, 2026.

Europe's Court of Justice dismissed Google and Alphabet's appeal on July 2, 2026, confirming a roughly €4.1 billion penalty over Android licensing practices and leaving no further right to appeal.

A coalition of 42 state attorneys general subpoenaed OpenAI on June 12, days after the company filed confidentially to go public, demanding records on advertising, health data, minors, and model sycophancy.

A February 1, 2026 deadline set by a White House executive order has passed with no final Part 108 rule, as a proposal granting drones presumptive right-of-way over manned aircraft draws heavy pushback.

Competition regulators in Italy and Brazil have ordered Meta to suspend its policy barring rival AI chatbots from WhatsApp, widening a fight that began in the EU.

The FDA's June 2 draft guidance lets genome-editing sponsors leverage prior CMC, nonclinical, and clinical knowledge across products, with a 90-day comment window.

The European Commission is finalizing a high triple-digit million euro fine — the largest ever under the Digital Markets Act — against Google for promoting its own Shopping, Flights, and Hotels services in search results.

EA shareholders approved the $55B PIF-led acquisition in late December; Canadian union CWA Canada has urged Ottawa to review the deal under the Investment Canada Act.

Meta filed a judicial review challenging Ofcom's use of qualifying worldwide revenue to set fees and penalties under the UK's Online Safety Act, with a full hearing scheduled for October.

FCC bureaus approved the transfer of 65 MHz to SpaceX for $17 billion and 50 MHz to AT&T for $23 billion on May 12, conditioning the deals on a $2.4 billion escrow account for tower-company claims.

Polis signed SB 26-189 on May 14, repealing the duty of care, impact assessments, and risk management mandates of SB 24-205 in favor of an ADMT notice-and-explain regime taking effect January 1, 2027.

The agency is asking patients, clinicians and researchers to nominate FDA-approved drugs that could be relabeled for new indications, including those backed by case reports or AI-generated preclinical evidence.